Moderate to severe pain, postoperative pain

Active Ingredient: Nalbuphine

Indication for Nalbuphine

Population group: only adults (18 years old or older)

Nalbuphine is indicated for the short-term relief of moderate to severe pain. It can also be used for pre- and post-operative analgesia.

For this indication, competent medicine agencies globally authorize below treatments:

0.4-1.2 mg/kg in 4 divided doses daily

Route of admnistration

Subcutaneous

Defined daily dose

0.4 - 1.2 mg per kg of body weight

Dosage regimen

From 0.1 To 0.3 mg per kg of body weight 4 time(s) per day every day

Detailed description

The usual recommended dose for adults is 10-20 mg for patients with 70 kg body weight, which is equivalent to 0.1–0.3 mg/kg body weight. This dose may be administered intravenously, intramuscularly or subcutaneously and may be repeated after 3 to 6 hours, if necessary. The maximum single dose in adults must not exceed 20 mg. The posology must be adapted to the intensity of pain and the physical status of the patient.

0.4-1.2 mg/kg in 4 divided doses daily

Route of admnistration

Intramuscular

Defined daily dose

0.4 - 1.2 mg per kg of body weight

Dosage regimen

From 0.1 To 0.3 mg per kg of body weight 4 time(s) per day every day

Detailed description

The usual recommended dose for adults is 10-20 mg for patients with 70 kg body weight, which is equivalent to 0.1–0.3 mg/kg body weight. This dose may be administered intravenously, intramuscularly or subcutaneously and may be repeated after 3 to 6 hours, if necessary. The maximum single dose in adults must not exceed 20 mg. The posology must be adapted to the intensity of pain and the physical status of the patient.

0.4-1.2 mg/kg in 4 divided doses daily

Route of admnistration

Intravenous

Defined daily dose

0.4 - 1.2 mg per kg of body weight

Dosage regimen

From 0.1 To 0.3 mg per kg of body weight 4 time(s) per day every day

Detailed description

The usual recommended dose for adults is 10-20 mg for patients with 70 kg body weight, which is equivalent to 0.1–0.3 mg/kg body weight. This dose may be administered intravenously, intramuscularly or subcutaneously and may be repeated after 3 to 6 hours, if necessary. The maximum single dose in adults must not exceed 20 mg. The posology must be adapted to the intensity of pain and the physical status of the patient.

Active ingredient

Nalbuphine

Nalbuphine is an opioid with kappa-agonistic and mu-antagonistic properties. Beside the essential agonistic (analgesic) effect nalbuphine has antagonistic effects of about a fourth of nalorfine and ten times of pentazocine.

Read more about Nalbuphine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.